Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026

Same author

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.

JAMA network open·2026

Same author

The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.

BJU international·2026

Same author

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026

Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026

Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026

Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026

Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026

Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026

Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 30, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Genetic Testing in Prostate Cancer.

Alexandra O Sokolova^1,2,3, Heather H Cheng^4,5

¹Department of Medicine, University of Washington, Washington, USA.

Current Oncology Reports

|January 25, 2020

Summary

This summary is machine-generated.

Genetic testing in prostate cancer (PCa) identifies mutations like homologous recombination repair (HR) and mismatch repair deficiency (MMRd). These findings guide targeted therapies such as PARPi and pembrolizumab, impacting treatment and family counseling.

Keywords:

BRCA Genetics Germline testing PARPi Prostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Related Experiment Videos

Last Updated: Dec 30, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Area of Science:

Oncology
Genetics
Molecular Biology

Background:

Prostate cancer (PCa) is a significant health concern.
Metastatic castration-resistant prostate cancer (mCRPC) presents therapeutic challenges.
Understanding the genetic landscape of PCa is crucial for personalized medicine.

Purpose of the Study:

To review recent advancements in prostate cancer genetics.
To highlight the clinical relevance of genetic mutations in PCa.
To discuss the implications of genetic testing for treatment and family counseling.

Main Methods:

Literature review of recent studies on PCa genetics.
Analysis of genetic mutation frequencies in mCRPC.
Synthesis of data on targeted therapy efficacy based on molecular profiles.

Main Results:

Over 20% of mCRPC tumors have homologous recombination (HR) repair gene mutations, with ~10% being germline.
~5% of mCRPC tumors exhibit microsatellite instability (MSI-H) and/or mismatch repair deficiency (MMRd).
Pembrolizumab is approved for MMRd tumors; PARPi and platinum chemotherapy show efficacy in HR-deficient PCa.

Conclusions:

Genetic testing in PCa patients provides prognostic information and identifies treatment options.
Germline and somatic tumor testing are increasingly recommended in specific clinical scenarios.
Targeted therapies like PARPi, platinum chemotherapy, and immune checkpoint inhibitors offer new hope for PCa patients with specific molecular features.